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Abstract
Objective: We aimed to describe the extent of neurodevelopmental impairments and 
identify the genetic etiologies in a large cohort of patients with epilepsy with myo-
clonic atonic seizures (MAE).
Methods: We deeply phenotyped MAE patients for epilepsy features, intellectual 
disability, autism spectrum disorder, and attention-deficit/hyperactivity disorder 
using standardized neuropsychological instruments. We performed exome analysis 
(whole exome sequencing) filtered on epilepsy and neuropsychiatric gene sets to 
identify genetic etiologies.
Results: We analyzed 101 patients with MAE (70% male). The median age of seizure 
onset was 34 months (range = 6-72 months). The main seizure types were myoclonic 
atonic or atonic in 100%, generalized tonic-clonic in 72%, myoclonic in 69%, absence 
in 60%, and tonic seizures in 19% of patients. We observed intellectual disability in 
62% of patients, with extremely low adaptive behavioral scores in 69%. In addition, 
24% exhibited symptoms of autism and 37% exhibited attention-deficit/hyperactivity 
symptoms. We discovered pathogenic variants in 12 (14%) of 85 patients, includ-
ing five previously published patients. These were pathogenic genetic variants in 
SYNGAP1 (n  =  3), KIAA2022 (n  =  2), and SLC6A1 (n  =  2), as well as KCNA2, 
SCN2A, STX1B, KCNB1, and MECP2 (n = 1 each). We also identified three new 
candidate genes, ASH1L, CHD4, and SMARCA2 in one patient each.
Significance: MAE is associated with significant neurodevelopmental impairment. 
MAE is genetically heterogeneous, and we identified a pathogenic genetic etiology 
in 14% of this cohort by exome analysis. These findings suggest that MAE is a mani-
festation of several etiologies rather than a discrete syndromic entity.
K E Y W O R D S
Doose syndrome, epilepsy/seizures, genetics, myoclonic astatic epilepsy
1 |  INTRODUCTION
Epilepsy with myoclonic atonic seizures (MAE), also known 
as myoclonic astatic epilepsy or Doose syndrome, is a rare 
epilepsy syndrome that occurs in 0.3%-2.2% of children 
with epilepsy.1,2 Children with MAE usually have normal 
development prior to seizure onset between 7  months and 
6 years. Seizure types include myoclonic atonic, atonic, myo-
clonic, generalized tonic-clonic, absence, and tonic seizures. 
Electroencephalogram (EEG) may exhibit irregular general-
ized spike-wave or polyspike-wave complexes.2 However, 
Key Points
• MAE is associated with significant neurodevelop-
mental impairment
• MAE is genetically heterogeneous, and a genetic 
etiology was identified in 14% of this cohort by 
exome analysis
• Severe neurodevelopmental comorbidity was observed 
in MAE patients with identified genetic etiology
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the variable combination of seizure types and developmental 
profile prior to seizure onset is open to interpretation, such 
that the phenotypic and nosological boundaries for this disor-
der remain debated.3
The spectrum of neurodevelopmental comorbidity in 
MAE has not been systemically described. Intellectual 
disability (ID) has been reported in 34%-60% of patients 
assessed with variable psychometric tools and different cog-
nitive definitions.2–6 Adaptive functioning, a collection of 
age-appropriate conceptual, social, and practical skills to 
enable a person to function in everyday life, has not been 
previously explored. Autism spectrum disorder (ASD) and 
attention-deficit/hyperactivity disorder (ADHD) symptoms 
have been documented in 5%-45% of very small case series 
and case reports.7,8
The importance of genetic factors in MAE was recognized 
through family history and EEG studies in its first descrip-
tion.2 Early twin studies and rare Mendelian pedigrees offered 
a glimpse of the genetic basis of MAE.9,10 Subsequently, the 
era of gene discovery through next generation sequencing 
and the recognition of the role of de novo variants in epilep-
tic encephalopathies (EE) and neurodevelopmental disorders 
has led to a multitude of gene associations for MAE.
Pathogenic variants in SCN1B,9 SCN1A,10 SLC2A1,11 
CHD2,12 SYNGAP1,13 KCNA2,14 STX1B,15 SLC6A1,16 
TBC1D24,17 KIAA2022,18 SCN2A,19 GABRB3,20 KCNT1,21 
STXBP1,21 MECP2,21 and AP2M122 have been reported in in-
dividuals with MAE, some overlapping with this cohort. 
However, although the number of implicated genes has ex-
panded to 16, the number of identified patients for each gene 
remains small, with the most enriched gene, SLC6A1, ac-
counting for only 3.7%. In addition, most gene discoveries 
were made in the context of EE patient cohorts, with very few 
MAE-specific discovery cohorts.
Here, we set out to provide a multifaceted analysis of the 
condition and describe deep phenotyping and exome sequenc-
ing in a cohort of 101 MAE patients. We present assumed 
pathogenic variants in seven unpublished and five previously 
described cases from single gene discovery studies.13–15,18,19,23
2 |  MATERIALS AND METHODS
2.1 | Subjects
MAE patients fulfilling the criteria of (1) onset of myoclonic, 
myoclonic atonic, or atonic seizures between 7 months and 
6 years; (2) presence of generalized spike or polyspike-wave 
EEG discharges; and (3) exclusion of other epilepsy syn-
drome24,25 were recruited through three cohorts. These were 
(1) the EuroEPINOMICS Rare Epilepsy Syndrome MAE 
cohort,14 (2) an Italian cohort collected through a tertiary 
pediatric neurology center at the Meyer Children's Hospital, 
and (3) a UK cohort (award ref MR/J011231/1, ethics ref 09/
H0713/76). Written informed consent was obtained from all 
parents/legal guardians of participating patients.
2.2 | Phenotyping methods
Medical notes including seizure types, presence of febrile 
convulsions, and EEG reports were obtained from referring 
clinical collaborators for the UK and Italian cohorts. Details 
from the EuroEPINOMICS cohort were available through an 
online password-protected platform.
All UK cases were phenotyped for adaptive function-
ing skills, ASD, ADHD, and behavioral screening rated 
by parent/carer and teacher where indicated. Additionally, 
families that lived close to King's Health Partners, London 
were invited for deep phenotyping for cognition using the 
Wechsler Preschool and Primary Scale of Intelligence–
Third UK Edition (WPPSI), Bayley Scales of Infant and 
Toddler Development–Third Edition (Bayleys), and 
Developmental, Dimensional and Diagnostic Interview 
(3di) rapid assessment. Deep phenotyping was assessed by 
a neuropsychologist or pediatric neurologist (S.T., A.S., 
M.A., D.K.P.).
2.2.1 | Adaptive behavior
Adaptive behavior was measured with the Adaptive 
Behaviour Assessment System (ABAS II) Parent Form. The 
ABAS II explores three domains: conceptual, social, and 
practical. The general adaptive composite score is derived 
from the sum of the three domains.
2.2.2 | Autism
Autism was measured with the Social Communication 
Questionnaire (SCQ) Autoscore Form: Lifetime and the 3di 
rapid assessment computerized interview.
2.2.3 | Behavior
Behavior was measured using Conners’ Comprehensive 
Behavioural Rating Scale (CBRS). The presence of signifi-
cant ADHD symptoms was assumed when a T score > 70 
was surpassed in subscale N. We also used the Strength and 
Difficulties Questionnaire (SDQ) as a behavioral screening 
questionnaire (www.sdqin fo.com). The SDQ has an impact 
supplement that enquires about chronicity, distress, social 
impairment, and burden to others. The scores were classified 
as close to average, slightly raised, high, or very high.
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2.3 | Analysis
SCQ scores were distributed by gender and compared 
with the Avon Longitudinal Study of Parents and Children 
(ALSPAC) population cohort (http://www.bris.ac.uk/alspa 
c/sci-com). Comparisons were performed using Student 
t test. SDQ comparisons using chi-square test were made 
with a normative sample of 10  298 British children aged 
5-15 years and with 73 children with established epilepsy 
excluding MAE.26,27
2.4 | Exome sequencing
Exome sequencing was performed at two centers. The 
EuroEPINOMICS cohort was sequenced at the Wellcome 
Trust Sanger Institute (Hinxton, Cambridgeshire, UK), and 
techniques have been described before.28 BAM files from the 
EuroEPINOMICS cohort were converted back to FASTQ 
files, and variant calling was reperformed using the Guy's 
Genomics Facility pipeline consistent with the remainder of 
the cohort. The Italian and UK cohorts were sequenced at the 
Guys Genomics Facility (Guy's Hospital, London, UK). DNA 
libraries were prepared using the SureSelect Human All Exon 
50 Mb Kit (Agilent Technologies). Samples were multiplexed 
(four samples on each lane), and 100-bp paired-end sequenc-
ing was performed on the Illumina HiSeq system. Sequencing 
reads were aligned using Novoalign (http://www.novoc raft.
com). FastQC was used to perform quality control on FASTQ 
files. Variant calling was performed with SAMtools, and anno-
tation was performed using ANNOVAR (http://annov ar.openb 
ioinf ormat ics.org). A read depth of 10 reads was the minimum 
cutoff, and heterozygous variants were called if the alternate al-
lele was present in >20% of total reads. All genetic variants are 
reported in human genome build GRCh37 (hg19) coordinates.
All variants of interest were annotated for minor allele 
frequency to the 1000 Genome Project (www.inter natio nalge 
nome.org), Exome Variant Server (http://esp.gs.washi ngton.
edu), Exome Aggregation Consortium (ExAC; http://exac.
broad insti tute.org), and the Genome Aggregation Database 
(http://gnomad.broad insti tute.org). Missense variants were 
annotated with a Combined Annotation Dependent Depletion 
(CADD) score (http://cadd.gs.washi ngton.edu), Sorting 
Intolerant From Tolerant (http://sift.jcvi.org), and PolyPhen 
(http://genet ics.bwh.harva rd.edu). Splice site prediction tools 
were AdaBoost and random forest provided by ANNOVAR. In 
addition, candidate genes were annotated with a residual vari-
ation intolerance score (RVIS) (http://genic-intol erance.org) 
and the ExAC Z score for missense variants. Gene expression 
in human central nervous system tissues was reviewed using 
GENEVESTIGATOR (http://genev estig ator.com).
2.5 | Gene and variant filtering
Variants were selected when not observed in 1000 Genome 
Project, Exome Variant Server, and ExAC and in genes over-
lapping with two gene lists: (1) the epilepsy-associated gene 
list (Table S1), consisting of 100 reported epilepsy-associated 
genes identified through various epilepsy sequencing stud-
ies; and (2) the neuropsychiatric gene list (Table S2), consist-
ing of 2105 genes curated from de novo sequencing studies of 
ID,29–31 developmental disorders,32 EE,33 and ASD.34–36 For 
variants matching a gene in the neuropsychiatric gene list, vari-
ants were reviewed if they had more than one filtered variant 
per gene with a CADD score > 20. All selected variants were 
then assessed based on genotype-phenotype correlation through 
PubMed literature search, gene intolerance, and gene expression 
(as above), and in some instances by locus-specific databases.
Sanger sequencing using standard methods from poly-
merase chain reaction (PCR) fragments was used to confirm 
all variants and for inheritance studies. Individual variants 
were classified as likely benign, variant of uncertain signif-
icance (VUS), pathogenic, or candidate variants. Variants 
were considered pathogenic if they were not present in con-
trol population data, were nonsynonymous, were splice site 
altering, were nonsense or frameshift, predicted damaging 
by one or more prediction tools, had consistent phenotype- 
genotype characteristics for gene, and were de novo. Likely be-
nign variants did not have supportive phenotype-genotype cor-
relations. VUS had unclear phenotype-genotype correlations 
and/or were inherited from an unaffected parent. Candidate 
variants were variants identified in genes that are not known to 
be associated with an epilepsy phenotype. Variants were inter-
rogated by a pediatric neurologist, a molecular geneticist, and a 
bioinformatics scientist (S.T., D.K.P., L.A.).
3 |  RESULTS
3.1 | Phenotype
We assembled 101 MAE patients (EuroEPINOMICS cohort, 
n = 31; Italian cohort, n = 13; UK cohort, n = 57) for pheno-
typing. There were 71 males (70.3%) and 30 females (29.7%). 
Table 1 details the main clinical characteristics of this cohort 
and compares it with previously published cohorts.
3.1.1 | Onset
The median age at seizure onset was 34  months (range = 
6-72 months) based on 100 probands. Twenty (21.0%) of 95 
patients had evidence of a developmental epileptic encepha-
lopathy where developmental delay was reported prior to epi-
lepsy onset; of these patients with prior developmental delay, 
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nine reported isolated speech delay prior to seizure onset. Six 
patients had missing information about early development. 
Twenty-eight (38.3%) of 73 patients had a personal history of 
febrile convulsions.
3.1.2 | Family history
A family history of epilepsy was reported in 36 of 95 
probands; a first-degree family member in 14 (of which one 
had MAE) and second- or higher-degree family member in 
22. A family history of febrile seizures was reported in six 
probands; family history was missing in six.
3.1.3 | Seizures
Seizure types at onset were generalized tonic-clonic seizures 
(GTCS) in 52 patients, myoclonic atonic or atonic in 31, myo-
clonic in 13, and absence in four of 100 patients. Seizure type at 
onset was missing for one patient. During the epilepsy course, 
mainly generalized seizure types were reported (see Table 1). 
Clinical examination, available in 92 patients, was abnormal in 
21 (22.8%), including tremor and/or ataxia in 15, pyramidal or 
motor signs in three, dysmorphism in two, and microcephaly 
in one. Dysmorphic features were described as prominent fore-
head, small eyes, large mouth, and syndactyly in one patient; 
and frontal balding, broad nasal bridge, thick alae nasi, broad 
and long philtrum, thin upper vermillion and thick lower ver-
million, skin wrinkling, upturned nasal tip, and anterior projec-
tion of the upper lip over premaxilla in the other patient.
3.1.4 | EEG
EEG background was slow during the epilepsy course in 16 
of 70 (22.8%) patients. EEG background data were not avail-
able for the EuroEPINOMICS cohort. One hundred patients 
had abnormal generalized epileptiform activity of spike-
wave discharges. Additional EEG features comprised poly-
spike and wave in 31 and focal epileptiform activity in seven.
3.1.5 | Neuroimaging
Computed tomography and/or magnetic resonance imaging 
reports were available for 78 patients. This was reported 
normal in 72 patients, with generalized cerebral volume 
loss in two, nonspecific focal signal alteration in two, and 
immature myelination and benign hydrocephalus in one pa-
tient each.
3.1.6 | Remission
Data regarding seizure remission, where seizure freedom 
was achieved for >2 years with or without antiepileptic 
drugs, were obtained for 72 patients within the UK and 
Italian cohorts. Twenty-four of 72 (33.3%) patients ful-
filled this definition of seizure remission. There was no 
statistical difference in the median age of seizure onset in 
both groups (32.5  months in remission group compared 
with 33.5 months in nonremission group, Mann-Whitney U 
test, P = .93). The most common antiepileptic drugs used 
T A B L E  1  Main clinical characteristics of epilepsy with myoclonic atonic seizures cohorts
Cohorts
This 
cohort
Caraballo et al
2013
Trivisano et al
2011
Kilaru & Bergqvist
2007
Nabbout et al
2003
Oguni et al
2002a
Kaminska et al
1999
Doose et al
1970
Cases, n 101 69 18 23 22 81 55 51
Boys, % 70 67 89 83 — 75 78 71
Febrile  
seizures, %
38 13 — 17 — — 16 22
Family history 
of Ep/FS, %
37/6 39/11 — 39/— 13/18 14/18 12/— 40/—
Mean age of 
onset, mo
32 39 43 36 40 32 35.6 36–48
Myo-atonic, % 100 100 100 61 100 100a 86 59
GTCS, % 72 72 78 70 77 93 87 71
Myoclonic, % 69 100 67 61 87 43 98 10
Absence, % 60 55 89 52 44 54 76 59
Tonic, % 19 40 39 0 27 — 46 2
Focal, % 4 — — — 8 — 0 6
Abbreviations: —, not available; Ep, epilepsy; FS, febrile seizures; GTCS, generalized tonic-clonic seizures; Myo-atonic, myoclonic atonic and/or atonic seizures.
aThis cohort was ascertained to assess treatment responsiveness of myoclonic atonic or atonic seizures, and therefore all patients had this seizure type. 
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in both groups were sodium valproate and clobazam, sug-
gesting patients likely to go into remission would respond 
to these medications.
3.2 | Neurodevelopmental comorbidity
3.2.1 | Cognition
ID was reported by the referring clinician in 61 (62.8%) of 
97 patients. Deep phenotyping with formal cognitive testing 
was available in 19 (WPPSI/Wechsler Intelligence Scale for 
Children, n = 14; Bayleys, n = 5) and showed eight with 
moderate to severe ID (intelligence quotient [IQ] < 70), five 
with mild ID (IQ = 7-85), and six as normal (IQ > 85).
3.2.2 | Adaptive behavior
Forty-six of 56 (response rate = 81%) ABAS II Parent 
Forms in the UK cohort were returned. Extremely low adap-
tive scores, which indicated a percentile rank ≤ 2nd, were 
seen in 27 (58.6%) patients for the conceptual, 15 (32.6%) 
for the social, and 31 (67.3%) for the practical domain. 
Correspondingly, 32 (69.5%) patients had extremely low 
general adaptive composite scores. Figure S1 shows the dis-
tribution of individual domain scores of the ABAS II.
3.2.3 | Autism
Fifty (38 males, 12 females) of 57 (response rate 87%) SCQ 
questionnaires were returned in the UK cohort. Fifteen (30%) 
patients reached the threshold for suspecting ASD with a 
score of ≥15. The mean score of 10.1 (SD = 7.41) was sig-
nificantly higher in both males and females when compared 
with the ALSPAC cohort (P < .0001; see Table S3). In ad-
dition, 3di interviews were conducted with one or both par-
ents of 19 patients. Based on the results of the 3di interview, 
eight patients had an ASD diagnosis. MAE patients reported 
the most difficulties in the social reciprocity domain, with a 
mean score of 8.43 (SD = 6.89) within the abnormal range 
for that subscale. Based on clinician report, two (25%) of 
eight patients in the Italian cohort and three (12%) of 25 pa-
tients in the EuroEPINOMICS cohort reported a diagnosis 
of ASD. Considering all these measures, 20 (24.1%) of 83 
patients reported either a diagnosis or symptoms of ASD.
3.2.4 | Behavior
Fifty of 56 SDQs (response rate = 89%) were returned in 
the UK cohort. High scores were returned in seven (14%) 
with emotional problems, 17 (34%) with conduct prob-
lems, 19 (38%) with hyperactivity problems, 21 (42%) 
with peer problems, 18 (36%) with prosocial problems, 
and 31 (62%) reporting these problems to significantly 
impact the family and child. The scores were significantly 
higher (P < .0001) in all domains except emotional symp-
toms when compared with a normative sample of British 
children, but were not significant when compared with 
children with established epilepsy excluding MAE (see 
Table S4).26,27
ADHD symptoms were ascertained through clinician 
reports in the Italian and EuroEPINOMICS cohorts and 
through the Parent and Teacher CBRS in the UK cohort. 
Two (25%) of eight patients in the Italian cohort, 13 (50%) 
of 26 patients in the EuroEPINOMICS cohort, and 13 
(32.5%) of 40 UK patients reported ADHD symptoms. 
Therefore, the estimated prevalence of ADHD symptoms 
in the entire cohort was 28 (37.8%) of 74 patients. Both 
parent and teacher CBRS scores were available in 34 UK 
patients. Table  S5 details the results of the parent and 
teacher CBRS scores.
3.2.5 | Multiple neurodevelopmental 
comorbidities
Patients for whom data for ID, ASD, and ADHD were avail-
able were analyzed for multimorbidity. Fifty of 70 (71.4%) 
patients had at least one comorbidity, and 22 of 70 (31.4%) 
had two or more comorbidities (Figure 1).
F I G U R E  1  Venn diagram demonstrating neurodevelopmental 
multimorbidity in 70 epilepsy with myoclonic atonic seizures patients. 
ADHD, attention-deficit/hyperactivity disorder; ID, intellectual 
disability
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3.3 | Exome sequencing
Of the 101 probands assembled in the phenotyping cohort, 
we exome sequenced 85 (EuroEPINOMICS cohort, n = 31; 
Italian cohort, n = 13; UK cohort, n = 41).
3.3.1 | Gene filtering using epilepsy-
associated genes
Pathogenic variants
Pathogenic variants in eight epilepsy-associated genes were 
identified in 12 patients (Table 2). This included seven un-
published and five previously described patients with variants 
in KCNA2 (n = 1),14 KIAA2022 (n = 2),18 SCN2A (n = 1),19 
SLC6A1 (n  =  2), STX1B (n  =  1),15 SYNGAP1 (n  =  3),13 
KCNB1 (n = 1), and MECP2 (n = 1). Of these, KCNB1 (volt-
age-gated potassium channel subfamily B member 1) vari-
ants have not been previously associated with MAE but have 
been reported in patients with EE and infantile epilepsy.37 
Subject 00 533 and the two other reported probands with the 
p.Arg306Cys variant all have an early onset epilepsy associ-
ated with severe ID. However, seizure types and EEG fea-
tures in these patients were variable.37,38
Likely benign variants and variants of uncertain 
significance
Six different variants from six different genes were classified 
as likely benign, and 15 variants in 12 genes were classified 
as VUSs (see Tables S6 and S7 and Appendix S1 for further 
discussion of each gene).
3.3.2 | Gene filtering using 
neuropsychiatric genes
Twenty-one genes from the neuropsychiatric gene set had 
nonsynonymous variants with CADD > 20 in the MAE co-
hort. There were no recurrent variant matches with the MAE 
cohort and the gene set variants. Eighteen genes were depri-
oritized due to RVIS > 25th percentile and negative ExAC 
Z score; or conflicting gene function; or inadequate nervous 
system expression; or unsupportive heterozygosity types 
or lack of segregation. Three genes, ASH1L, CHD4, and 
SMARCA2, remained as possible candidate genes (Table 3).
ASH1L (absent, small or homeotic disc 1 like histone ly-
sine methyltransferase) encodes histone methyltransferase, 
which is involved in histone and chromatin modification and 
gene regulation. Ash1L is enriched in the brain in mice, and a 
role in epigenetic modification in brain functioning was im-
plicated when in Ash1L knockout mice the activity-dependent 
repression of neurexin 1α, a presynaptic adhesion molecule 
required for synaptic formation, was completely abolished.39 
CHD4 (chromodomain helicase DNA binding protein 4) is an 
adenosine triphosphate (ATP)-dependent chromatin remod-
eler involved in epigenetic regulation of gene transcription, 
DNA repair, and cell cycle progression.40 It is also a paral-
ogue of CHD2, which is associated with MAE.12 SMARCA2 
mutations are associated with Nicolaides-Baraitser syn-
drome. It is one of six genes that encode the SWItch/sucrose 
nonfermentable like chromatin remodeling complex and 
alters chromatin structure through ATP hydrolysis. Subject 
3003 301, with a de novo p.Gln1241Glu SMARCA2 variant, 
was subsequently identified as also having clinical features 
compatible with a diagnosis of Nicolaides-Baraitser syn-
drome along with MAE.23
4 |  DISCUSSION
This paper uses a large cohort of patients with MAE (n = 101) 
to describe the phenotypic variability in seizures and a high 
incidence of neurodevelopmental comorbidities. We report a 
genetic cause in 14% with some associated motor symptoms. 
The findings pose questions for the nosological boundaries of 
MAE and overlap with genetic generalized epilepsies (GGEs) 
and developmental epileptic encephalopathies (DEEs).
Although the most frequent seizure types in MAE are as 
expected (myoclonic atonic or atonic seizure, 100%; GTCS, 
72.7%; and myoclonic seizures, 68.2%),3,5,6,41 a minority of 
MAE patients have focal seizures, some (6.9%) with addi-
tional focal epileptiform activity on EEG. Focal EEG fea-
tures have been reported in up to 39% of MAE cohorts40 and 
have been proposed as a marker of poor prognosis in MAE.42 
However, we were not able to confirm this hypothesis in this 
cohort, as two of seven patients with focal EEG abnormalities 
achieved seizure remission, compared to 22 of 70 patients 
without focal abnormalities.
Approximately 20% of patients had evidence of a DEE 
with developmental or speech delay prior to onset of seizures, 
a much higher frequency of antecedent impairments than 
was previously appreciated. ID was reported in 61 (62.8%) 
of 97 patients, and the impact of these deficits is reflected 
in extremely low adaptive functioning in 32 (69.5%) of 46 
patients. ASD symptoms occurred in 24.1%, possibly due to 
predisposing factors such as ID, early onset of seizures, and 
EE. ADHD symptoms, predominantly inattentive, were iden-
tified in 37.8%, in keeping with other pediatric epilepsies.
The variation in phenotype overlaps with other epilepsy 
syndromes, and we recognize that the current concept of 
MAE provides a phenotypic bridge between GGEs and DEEs, 
including Lennox-Gastaut syndrome. For example, anteced-
ent neurodevelopmental impairments and autistic and cog-
nitive deficits are more characteristic of DEE.43 Moreover, 
Eschbach et al reported that more than one-half of a cohort of 
77 patients with suspected MAE undergo epilepsy diagnosis 
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switching.40 However, we believe that the MAE concept re-
mains broadly useful to guide treatment and prognosis.
Unsurprisingly, cases with neurodevelopmental symp-
toms or neurological signs were more likely to have an 
identified genetic etiology. ID was reported in 11 of 12 
(3/3 candidate) patients, ASD in five of 12 (2/3 candi-
date) patients, and ADHD in three of 12 (1/3 candidate) 
patients. ID, ASD, and epilepsy share causative genes 
and biological pathways including gene transcription reg-
ulation, neurotransmission, and maintenance of synaptic 
structure. These neurodevelopmental comorbidities may 
be a primary feature of the genetic disease rather than 
secondary to disturbance of brain function due to exces-
sive epileptiform activity (an epileptic encephalopathy). 
Abnormal neurological findings were reported in 21 of 92 
patients, higher than the 12% in previous smaller MAE se-
ries.2,41 Ataxia and tremor have been recognized in MAE 
patients with pathogenic variants in SLC2A1,11 STX1B,15 
and SLC6A116 and occurred in our probands with patho-
genic variants in SYNGAP1 (n = 3) and MECP2 (n = 1). 
These motor signs may be useful in suggesting specific 
genotype correlation in MAE.
The expansion of the phenotype has consequently led 
to expansion of the genetic spectrum. We identified patho-
genic variants in 12 (14.1%) of 85 patients. These included 
seven unpublished and five previously described patients 
with KCNA2 (n  =  1),14 KIAA2022 (n  =  2),18 SCN2A 
(n  =  1),19 SLC6A1 (n  =  2), STX1B (n  =  1),15 MECP2 
(n = 1), KCNB1 (n = 1), and SYNGAP1 (n = 3).12 We also 
present candidate genes ASH1L, CHD4, and SMARCA221 
in one patient each.
Gene-specific features were observed. Our subjects 
with SYNGAP1 variants all had seizure onset in infancy, 
ID, ataxia, and hypotonia consistent with a SYNGAP1 en-
cephalopathy.13 The two female subjects with p.Leu421fs 
and p.Arg322* KIAA2022 variants both have MAE comor-
bid with ID. Subject 291J with a de novo MECP2 p.Pro-
225Thr variant has overlapping clinical features found 
in classic Rett syndrome of cerebellar signs and an EEG 
with a disorganized background. De novo MECP2 vari-
ants are recognized as causative for MAE and other epi-
lepsies.21,44 A potential clinical implication is that children 
with Rett syndrome have an increased risk of life-threat-
ening arrhythmias associated with prolonged QTc interval 
and should avoid drugs known to prolong QTc interval. It 
is unknown whether this also applies to patients with an 
MECP2-associated epilepsy.
Atypical EEG features should prompt a search for a 
genetic etiological link as demonstrated in our cases with 
KCNA2 and KCNB1. Moreover, subject 00595 with an 
SLC6A1 variant had an unusual EEG feature of posterior 
eye closure sensitivity with 3- to 4-Hz spike-wave com-
plexes on the posterior third of the head provoked by eye 
closure, similarly identified in one of seven other MAE 
cases with SLC6A1 variants.16
Finally, we identified ASH1L and CHD4 as candidate 
genes in this paper. Seven other de novo ASH1L variants 
have been reported in ID/ASD patients.45,46 Only one case 
has been described with an epilepsy phenotype; the patient 
had a missense ASH1L variant of unknown inheritance, 
leaving its pathogenic role uncertain.46 The highly con-
served p.Arg1342* variant identified here is located be-
tween two annotated protein domains, like other reported 
mutations.46 A de novo CHD4 variant has been reported 
in a single patient with EE, and individuals with overlap-
ping phenotypes of developmental delay, hearing loss, 
macrocephaly, distinct facial dysmorphisms, palatal ab-
normalities, ventriculomegaly, and hypogonadism but no 
epilepsy.33,47 The variant p.His896Arg identified in subject 
00526 is located within the ATPase/helicase domain and 
may disrupt the ATPase activity of CHD4. Further stud-
ies are required to understand the phenotypic variability of 
CHD4 mutations.
There were several limitations in this study. The ascer-
tainment of patients may have been biased toward more 
severe phenotypes. Patients were recruited from differ-
ent European countries, which may have contributed to 
phenotypic heterogeneity. Many cases were phenotyped 
through screening questionnaires, which does not substi-
tute for direct neuropsychological testing. Whole exome 
sequencing has poor capacity to identify structural variants 
and somatic mosaic variants, and this was not investigated. 
Additionally, in silico prediction tools were available only 
for missense variants, and the role of indels and frameshift 
variants may be underestimated.
Several lines of enquiry remain for the unsolved MAE 
cases. While there are remaining undiscovered genes within 
the exome space, the impact of variants in noncoding re-
gions, regulatory regions, and microRNAs remain to be 
interrogated and may be revealed with whole genome se-
quencing. Copy number variations (CNVs) in this cohort 
were not investigated, but from previous studies we would 
expect a frequency of pathogenic CNVs in 5% of cases.48,49 
Somatic mosaic variants are increasingly recognized in early 
onset genetic disease and remain challenging to investigate.50 
Susceptibility genetic factors and rare variants contributing 
to specific phenotypic features such as seizure types and EEG 
features remain undetermined.
In summary, we demonstrated that MAE is associated 
with significant neurodevelopmental comorbidity and the 
yield of identifying a possible monogenetic etiology was 
about 14% in this cohort. An identifiable genetic etiology was 
more likely in patients with associated neurodevelopmental 
disorders and brings the possibility of personalized medicine 
closer, such as the use of the ketogenic diet in patients with 
GLUT1 deficiency, sodium channel blockers in patients with 
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KCNQ2, SCN2A, and SCN8A mutations, and the promise of 
gene-specific small molecular ion channel modulators and 
antisense oligonucleotides. This genetic heterogeneity sug-
gests a concept that the MAE phenotype might be a common 
manifestation of several etiologies rather than a discrete syn-
dromic entity.
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